
News|Videos|December 9, 2016
Using FDG-PET to Guide Hodgkin Lymphoma Treatment
Author(s)Peter Johnson, MD
This interview examines the role of functional imaging to direct therapy (escalation or de-escalation) for early and advanced Hodgkin lymphoma.
Advertisement
In this interview, Peter Johnson, MD, of the University of Southampton in the United Kingdom, discusses the results of trials testing the role of FDG–positron emission tomography (PET) to direct therapy (escalation or de-escalation) for patients with both early and advanced Hodgkin lymphoma.
Dr. Johnson spoke at an education session on how Hodgkin lymphoma is treated today and the challenges ahead at the 58th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
2
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
3
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
4
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
5

























































